Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period.

[1]  M. Scorsetti,et al.  Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis , 2021, Clinical & Experimental Metastasis.

[2]  C. Kornhuber,et al.  Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis , 2021, International journal of cancer.

[3]  C. Porta,et al.  Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival , 2021, JAMA network open.

[4]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[5]  S. Keevil,et al.  Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. , 2021, The Lancet. Oncology.

[6]  B. Heijmen,et al.  The Dutch-Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases. , 2020, International journal of radiation oncology, biology, physics.

[7]  B. Yaremko,et al.  Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial , 2020, medRxiv.

[8]  D. Gomez,et al.  Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer. , 2020, The Journal of thoracic and cardiovascular surgery.

[9]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[10]  A. Gottschalk,et al.  Stereotactic body radiotherapy of adrenal metastases: a pooled meta-analysis and systematic review of 39 studies with 1006 patients. , 2020, International journal of radiation oncology, biology, physics.

[11]  I. Kaplan,et al.  The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. , 2019, European urology focus.

[12]  Suresh Senan,et al.  Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases. , 2018, International journal of radiation oncology, biology, physics.

[13]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  J P Cuijpers,et al.  Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  David A. Palma,et al.  The oligometastatic state—separating truth from wishful thinking , 2014, Nature Reviews Clinical Oncology.

[16]  Laura H. Tang,et al.  Laparoscopic Adrenalectomy for Isolated Adrenal Metastasis , 2007, Annals of Surgical Oncology.

[17]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of surgery.

[18]  K. Lam,et al.  Metastatic tumours of the adrenal glands: a 30‐year experience in a teaching hospital , 2002, Clinical endocrinology.

[19]  B. J. Harrison,et al.  Comparison of open posterior versus transperitoneal laparoscopic adrenalectomy , 1999, The British journal of surgery.

[20]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.